Comparative safety of ICS/LABA fixed combinations

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2019年 / 1782卷 / 1期
关键词：
D O I：
10.1007/s40278-019-72177-x
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：8 / 8
相关论文
共 50 条
  • [41] Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS
    Latorre, M.
    Novelli, F.
    Vagaggini, B.
    Braido, F.
    Papi, A.
    Sanduzzi, A.
    Santus, P.
    Scichilone, N.
    Paggiaro, P.
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2015, 30 : 44 - 50
  • [42] CURRENT PATTERNS OF FIXED AND FREE LABA/ICS COMBINATION USAGE IN ASTHMA SHI PATIENTS IN GERMANY
    Bonthapally, V
    Wolbring, F.
    Sindern, J.
    Mehnert, A.
    VALUE IN HEALTH, 2009, 12 (03) : A128 - A128
  • [43] Efficacy and safety of ICS/LABA/LAMA FDCs in COPD: a network meta-analysis
    Rogliani, P.
    Cazzola, M.
    Verri, S.
    Camardelli, F.
    Calzetta, L.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [44] Single Inhaler Triple-Therapy (ICS/LAMA/LABA) Versus Dual-Therapy (ICS/LABA or LAMA/LABA) in Patients with COPD at Risk of Exacerbations: Efficacy and Safety Results of the Phase III IMPACT Trial
    Lipson, D. A.
    Barnhart, F.
    Brealey, N.
    Day, N. C.
    Brooks, J.
    Criner, G.
    Dransfield, M. T.
    Halpin, D. M.
    Han, M. K.
    Jones, C.
    Kilbride, S.
    Lange, P.
    Lomas, D. A.
    Martinez, F. J.
    Singh, D.
    Tabberer, M.
    Wise, R. A.
    Pascoe, S. J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [45] Clinical efficacy and safety of ICS/LABA in patients with combined idiopathic pulmonary fibrosis and emphysema
    Dong, Fushi
    Zhang, Yimei
    Chi, Fangzhou
    Song, Qi
    Zhang, Lijuan
    Wang, Yupeng
    Che, Chunli
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (06): : 8617 - 8625
  • [46] A review of current and developing fixed-dose LABA/LAMA combinations for treating COPD
    Lal, Chitra
    Strange, Charlie
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (17) : 1833 - 1843
  • [47] Inhaler Devices for Delivery of LABA/LAMA Fixed-Dose Combinations in Patients with COPD
    Anthony D’Urzo
    Kenneth R. Chapman
    James F. Donohue
    Peter Kardos
    M. Reza Maleki-Yazdi
    David Price
    Pulmonary Therapy, 2019, 5 : 23 - 41
  • [48] Inhaler Devices for Delivery of LABA/LAMA Fixed-Dose Combinations in Patients with COPD
    D'Urzo, Anthony
    Chapman, Kenneth R.
    Donohue, James F.
    Kardos, Peter
    Maleki-Yazdi, M. Reza
    Price, David
    PULMONARY THERAPY, 2019, 5 (01) : 23 - 41
  • [49] Evaluation of Time-to-First COPD Exacerbation in Patients Diagnosed with COPD Initiating Maintenance Therapy with Inhaled Fixed-Dose Combinations of LAMA/LABA or ICS/LABA Within a Large US Health Insurer Database
    Moretz, C.
    Sharpsten, L.
    Bengtson, L. G. S.
    Koep, E.
    Le, L.
    Tong, J.
    Hahn, B.
    Stanford, R. H.
    Asmus, M. J.
    Ray, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [50] The role of fixed dose combinations of inhaled cortikosteroids, long acting beta-2 agonists, and long acting muscarinic antagonists (ICS/LABA/LAMA) in the treatment of asthma
    Metan, Esra Unsay
    Bavbek, Sevim
    TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX, 2021, 69 (03): : 369 - 379
12345